Skip to main content
SYRE
NASDAQ Life Sciences

Spyre Therapeutics 8-K Confirms $350M Offering at $85/Share

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$80.51
Mkt Cap
$7.064B
52W Low
$15.86
52W High
$110.175
52W Position info
408% above low
Off High info
27% below high
Rel. Volume info
3.6× avg
Market data snapshot near publication time

SYRE has more than doubled off its 52-week low of $15.86 on elevated volume (3.6× avg).

Summary

Spyre Therapeutics confirmed its $350 million public offering of 4,117,648 shares at $85 per share, with underwriters holding a 30-day option for 617,647 additional shares. Proceeds fund pipeline development including a new SPY072 program for hidradenitis suppurativa.


Key Events · Financing and Capital Events · SYRE

  • $350M Public Offering Priced at $85/Share

    On October 5, 2026, an underwriting agreement was entered into to sell 4,117,648 shares of common stock at $85.00 per share, generating approximately $350.0 million in gross proceeds before underwriting discounts and expenses.

  • Underwriter Option for 617,647 Additional Shares

    Underwriters received a 30-day option to purchase up to 617,647 additional shares on the same terms, potentially increasing the offering size by approximately $52.5 million if fully exercised.

  • Underwriter Purchase Price Set at $79.90

    Underwriters will pay $79.90 per share, representing a $5.10 per share underwriting discount (6.0%) from the $85.00 public offering price.

  • Proceeds Fund Pipeline Including New SPY072 Program

    Net proceeds will advance gastroenterology, rheumatology, and dermatology programs, including a new initiative to advance SPY072 into late-stage development for hidradenitis suppurativa, plus general infrastructure and potential in-licensing or acquisitions.


Analysis · SYRE · Life Sciences

A $350 million public offering was formalized through an underwriting agreement with Jefferies, TD Securities, Leerink Partners, and Stifel. The deal prices 4,117,648 shares at $85.00 per share, with underwriters paying $79.90 per share and holding a 30-day option for 617,647 additional shares. Proceeds fund the company's gastroenterology, rheumatology, and dermatology programs, including a new push to advance SPY072 into late-stage development for hidradenitis suppurativa. The offering closes on or about October 7, 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SYRE was trading at $80.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $15.86 to $110.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SYRE - Latest Insights

SYRE
Nov 03, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $93.47 info
Change: -$6.26 (-6%) info
Market Cap: $8.877B info
SYRE
Nov 03, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $93.47 info
Change: -$6.26 (-6%) info
Market Cap: $8.877B info
SYRE
Oct 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $80.11
Real-time Price: $93.47 info
Change: +$13.36 (+17%) info
Market Cap: $8.877B info
SYRE
Oct 06, 2026, 11:53 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $81.16
Real-time Price: $93.47 info
Change: +$12.31 (+15%) info
Market Cap: $8.877B info
SYRE
Oct 05, 2026, 4:03 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $89.81
Real-time Price: $93.47 info
Change: +$3.66 (+4%) info
Market Cap: $8.877B info